Healio

As-needed albuterol-budesonide reduces risk for severe asthma exacerbations

Please provide your email address to receive an email when new articles are posted on . BATURA showed a 47% reduction in severe exacerbation risk with albuterol budesonide vs. albuterol in patients ...
Monthly Prescribing Reference

As-Needed Albuterol/Budesonide Reduces Exacerbations in Patients With Mild Asthma

Severe exacerbation occurred in 5.1% of patients taking albuterol/budesonide compared with 9.1% of patients taking albuterol alone in the on-treatment efficacy population. Albuterol/budesonide ...
Healio

Fixed-dose albuterol-budesonide inhaler lowers severe exacerbation risk in mild asthma

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.
Seeking Alpha

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced publication in The Lancet of the full data from the Phase 3 NefIgArd ...